Advertisement

Diabetologia

, Volume 61, Issue 9, pp 1913–1917 | Cite as

The chicken or the egg? Does glycaemic control predict cognitive function or the other way around?

  • Ithamar Ganmore
  • Michal Schnaider BeeriEmail author
Commentary

Abstract

The association between type 2 diabetes and cognitive dysfunction is well established. Prevention of the development of type 2 diabetes and its complications, as well as cognitive dysfunction and dementia, are leading goals in these fields. Deciphering the causality direction of the interplay between type 2 diabetes and cognitive dysfunction, and understanding the timeline of disease progression, are crucial for developing efficient prevention strategies. The prevailing perception is that type 2 diabetes leads to cognitive dysfunction and dementia. There is substantial evidence showing that accelerated cognitive decline in type 2 diabetes starts in midlife (mean age 40–60 years) and that it may even begin at the prediabetes stage. However, in this issue of Diabetologia, Altschul et al (doi:  https://doi.org/10.1007/s00125-018-4645-8) show evidence for the reverse causality hypothesis, i.e. that lower cognitive function precedes poor glycaemic control. They found that cognitive function at early adolescence (age 11 years) predicts both HbA1c levels and cognitive function at age 70 years. Moreover, they found that lower cognitive function at age 70 is associated with an increase in HbA1c from age 70 to 79 years. Based on these findings, future studies should explore whether developing prevention strategies that target young adolescents with lower cognitive function will result in prevention of type 2 diabetes, breaking the vicious cycle of type 2 diabetes and cognitive dysfunction.

Keywords

Adolescence Cognitive decline Cognitive function Dementia Diabetes HbA1c Prevention Type 2 diabetes 

Abbreviations

LBC1936

Lothian Birth Cohort of 1936

MCI

Mild cognitive impairment

Introduction

Type 2 diabetes is one of the modern era epidemics [1] and preventing its development and complications are two of the most important goals in the field. Cognitive dysfunction in old age [2], which is associated with type 2 diabetes [3, 4], might result in another modern era epidemic, dementia. Development of both type 2 diabetes and dementia is partially attributed to modifiable risk factors, including glycaemic control [5, 6]. When developing prevention strategies, several factors must be well defined, including the intervention target, the most susceptible population, and the age range at which the intervention may have the highest preventive potential. In this issue of Diabetologia, the study by Altschul et al, which used the Lothian Birth Cohort of 1936 (LBC1936) [7], presents tantalising findings related to the interplay between glycaemic control and cognitive dysfunction. This study examined the association of cognitive function at early life (age 11 years) and late life (age 70 years), and of cognitive decline from age 70 to 79 years, with HbA1c at age 70 and its change from age 70 to 79. The cognitive domains tested were memory, processing speed, visuospatial ability and crystallised ability, which were combined to create a global cognition measure. The authors found that cognitive function at age 11 predicts both HbA1c levels and cognitive function at age 70. They also showed that lower cognitive function at age 70 is associated with an increase in HbA1c from age 70 to 79. HbA1c level at age 70 was not consistently associated with cognitive function at age 70 or with the decline of cognitive function from age 70 to 79 [7] (summarised in Fig. 1).
Fig. 1

A simplified schematic showing the main findings from the study by Altschul [7]. This study examined whether cognitive function at early life (age 11 years) and late life (age 70 years), and cognitive decline from age 70 to 79 years, were associated with HbA1c at age 70 and its change (HbA1c slope) from age 70 to 79. Rectangles represent cognitive function/decline; ovals represent HbA1c level/slope. Arrows indicate associations tested: blue arrows, statistically significant; red arrows, not statistically significant

HbA1c is the gold standard measure of glycaemic control and a surrogate for analysis of complications associated with type 2 diabetes [8]. Moreover, HbA1c predicts type 2 diabetes and is useful for identifying individuals with elevated type 2 diabetes risk [9]. Hence, Altschul et al’s findings shed light on two important aspects relevant to the development of prevention strategies for both type 2 diabetes and cognitive dysfunction: the direction of causality and the timeline in the interplay of type 2 of diabetes with cognitive dysfunction. Disentangling the direction of causality may help to elucidate the mechanisms of cognitive dysfunction and type 2 diabetes, in order to develop relevant intervention tools. Identifying periods in life when cognitive dysfunction and type 2 diabetes affect each other may point to the most effective window of opportunity for intervention. In this commentary, we elaborate on both of these aspects.

The chicken or the egg: which comes first, poor glycaemic control or cognitive dysfunction?

Type 2 diabetes is associated with elevated risks for cognitive dysfunction, accelerated cognitive decline, mild cognitive impairment (MCI) and dementia [4]. Importantly, type 2 diabetes in midlife (when cognitive dysfunction due to a neurodegenerative process is very rare) has been strongly associated with late-life dementia. This suggests that type 2 diabetes may predict dementia [10]. However, some evidence suggests otherwise, as discussed below.

Type 2 diabetes precedes cognitive dysfunction

The prevailing perception is that type 2 diabetes leads to cognitive dysfunction and dementia. We have recently published a comprehensive summary of 119 studies, comparing cognitive function between individuals without diabetes with that of those with type 2 diabetes in different stages of the disease (prediabetes, newly diagnosed type 2 diabetes, and prevalent type 2 diabetes at midlife, old age and very old age) [3]. There were two main findings from this summary; first, cross-sectionally, elderly individuals (mean age 60–80) with prevalent type 2 diabetes (i.e. who were not newly diagnosed) performed worse in both global cognitive function, as well as the cognitive subdomains tested (memory, attention, executive function, language and perceptual-motor), except for the subdomain of semantic memory. In contrast, other participant subgroups (individuals with prediabetes, newly diagnosed type 2 diabetes, and prevalent type 2 diabetes at midlife or very old age) had similar cognitive function to individuals without diabetes in most cognitive subdomains. Second, longitudinally, the accelerated cognitive decline over time in type 2 diabetes in most cognitive subdomains is most evident in midlife [3] and might even begin at the prediabetes stage [11], suggesting that the deleterious effects of type 2 diabetes on the brain may begin early in the type 2 diabetes process.

Additionally, characteristics related to type 2 diabetes, including higher blood glucose levels, higher serum fasting insulin and insulin resistance [12, 13, 14], have been linked to cognitive dysfunction, accelerated cognitive decline and dementia in elderly individuals, even in those without diabetes [14, 15]. Moreover, in addition to blood glucose and HbA1c levels, poor long-term HbA1c trajectories [16] and glucose peaks [17] have been shown to be associated with cognitive function.

Although it may seem surprising that Altschul et al [7] did not find an association of HbA1c level at the age of 70 with cognitive function at the same age, or with cognitive decline at age 70–79, a few possible explanations are proposed. As noted above, individuals with prevalent type 2 diabetes have poorer cognitive function than those without diabetes. The main analyses by Altschul et al were not stratified by type 2 diabetes diagnosis [7], possibly masking the association of HbA1c with cognition, which is stronger among individuals with type 2 diabetes [18]. This is particularly relevant in the LBC1936 cohort, where the prevalence of type 2 diabetes is relatively low (7–12% depending on the year of assessment). The prevalence of type 2 diabetes in the Lothian region for individuals aged over 65 years is 15% [19], and in the United States it is 20% [20]. This interpretation is reinforced by the results of the secondary analyses which excluded participants with type 2 diabetes patients, as effect sizes were slightly reduced, suggesting that even the very small number of individuals with type 2 diabetes had a substantial impact on the results. Also, the use of medication for type 2 diabetes, which was not specified in the study, might have normalised or improved glycaemic control in those taking it, further masking potential associations between HbA1c and cognition.

The lack of an association between HbA1c and cognitive decline at age 70–79, may be additionally explained by the cognitive domains assessed in the study, which included memory, processing speed, visuospatial ability and crystallised ability. In previous studies, type 2 diabetes status has not been associated with decline in these domains in participants within the same age range [21, 22, 23, 24]. In contrast, other studies found greater decline in other cognitive domains, such as attention, executive functions, motor and perceptual abilities, when compared with individuals without diabetes [24, 25, 26, 27]. This reflects the complexity of the relationship between type 2 diabetes and cognition, suggesting that type 2 diabetes may affect specific brain regions that underlie particular cognitive functions [28].

Lower cognitive dysfunction precedes type 2 diabetes

Contrary to the predominant perception, Altschul et al’s findings [7] present evidence for an alternative hypothesis of reverse causality: lower cognitive function leads to poor glycaemic control. This is consistent with previous studies by the same research group, where cognitive function at age 11 has been shown to be associated with type 2 diabetes status and HbA1c levels at the age of 70 [29, 30]. In line with this, lower cognitive function at late adolescence (age 17 years) has been associated with elevated risk for impaired fasting glucose and future type 2 diabetes [31, 32]. Furthermore, Altschul et al [7] showed that poorer cognitive function at the age of 70 is associated with increasing HbA1c levels over the following decade.

The reverse causality hypothesis has several possible explanations. Poor cognitive function may lay the foundation for ‘health illiteracy’ and poor health management skills, such as physical inactivity, that increase the risk of type 2 diabetes and its risk factors (e.g. obesity) [33]. The attenuation of the association between cognitive function at age 11 and type 2 diabetes at the age of 70 after adjusting for BMI and cholesterol level support this explanation [30]. An alternative explanation for the reverse causality hypothesis is that there is a third common driver for both cognitive dysfunction and type 2 diabetes, such as a pleiotropic gene, similar to the pleiotropic genes that lead to both type 2 diabetes and obesity independently [34].

A ‘vicious cycle’ of type 2 diabetes and cognitive dysfunction

The two hypotheses described above may not be mutually exclusive. For example, early-life lower cognitive function might lead to type 2 diabetes, which then might lead to worse cognitive function, eliciting a ‘vicious cycle’. Difficulties in performing self-care tasks, such as glucose monitoring and adhering to diet and medication (including adjustment of insulin dose), possibly contributes to this vicious cycle [35]. These difficulties might result in higher prevalence of hyperglycaemic and hypoglycaemic states, both of which may aggravate type 2 diabetes complications, including deterioration of cognitive function [36, 37]. Since hypoglycaemia is the main limiting factor in glucose-lowering therapy, with possibly fatal outcomes, the ADA recommends relaxed glycaemic goals for patients with even MCI; the recommended target HbA1c is <64–69 mmol/mol (<8.0–8.5%) for these individuals, whilst for patients with type 2 diabetes with few coexisting chronic illnesses and intact cognitive function, it is 58 mmol/mol (7.5%) [35].

Timeline of the interplay between type 2 diabetes with cognitive dysfunction

Both type 2 diabetes and dementia are often perceived diseases of older age. However, the preclinical incipient period (i.e. when insulin resistance and beta cells dysfunction develop in diabetes or dementia-related neuropathology aggregation commences) begins years, if not decades before clinical symptoms are manifested [38, 39]. Thus, prevention of these diseases must begin at early stages, although the precise time point for intervention is unknown and may depend on individual variability. The association between cognitive function in early adolescence (age 11) and type 2 diabetes risk in older age (age 70) [7, 29, 30] suggests that targeting individuals with lower cognitive function at a young age may improve life-long health. Promoting health education and awareness, and encouraging healthy behaviours may help to prevent type 2 diabetes or ameliorate its effects, possibly ‘breaking’ the vicious cycle. However, further studies are required before it is clear at what ages such interventions would be effective.

Perspective

In this commentary, we have presented some of the findings related to the interplay of type 2 diabetes with cognitive dysfunction. These findings provide additional evidence in favour of the development of strategies for prevention of both conditions. Since accelerated cognitive decline in type 2 diabetes begins in the first few years following type 2 diabetes diagnosis [3], and possibly even in the prediabetic stage [11], efforts to prevent diabetes and, thus, cognitive decline (as well as other complications of type 2 diabetes), should start then. This does not detract from late-life efforts to prevent type 2 diabetes complications, which include cognitive dysfunction. Even among elderly individuals with type 2 diabetes, good trajectories of glycaemic control are associated with better cognitive function [16]. However, long-term damage from the interplay between hyperglycaemia and cognitive dysfunction may limit effectiveness of preventive interventions in old age.

In addition, the findings by Altschul et al [7], along with others [29, 30, 31, 32], support the concept that early-life cognitive function is associated with the risk for developing type 2 diabetes (or related characteristics, such as poor glycaemic control) in late life. This underlies the hypothesis that early adolescents with lower cognitive function may be at risk for developing type 2 diabetes later in life, and that there may be value in targeting preventive intervention strategies at this age group. Of course, decreasing type 2 diabetes risk in late life (and possibly dementia risk) by improving early-life health literacy and other relevant modifiable lifestyle factors, is an enormous endeavour that must be examined empirically.

Notes

Contribution statement

Both authors were responsible for drafting the article and revising it critically for important intellectual content. Both authors approved the version to be published.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

References

  1. 1.
    Zimmet PZ (2017) Diabetes and its drivers: the largest epidemic in human history? Clin Diabetes Endocrinol 3:1CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Larson EB, Yaffe K, Langa KM (2013) New insights into the dementia epidemic. N Engl J Med 369:2275–2277CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ganmore I, Beeri MS (2018) Magnitude and trajectories of cognitive dysfunction in type 2 diabetes mellitus. In: Srikanth V, Arvanitakis Z (eds) Type 2 diabetes and dementia. Elsevier, New York, pp 29–47CrossRefGoogle Scholar
  4. 4.
    Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA (2014) Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol 2:246–255CrossRefPubMedGoogle Scholar
  5. 5.
    Gonzalez-Bulnes A, Astiz S, Ovilo C, Garcia-Contreras C, Vazquez-Gomez M (2016) Nature and nurture in the early-life origins of metabolic syndrome. Curr Pharm Biotechnol 17:573–586CrossRefPubMedGoogle Scholar
  6. 6.
    Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 10:819–828CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Altschul DM, Starr JM, Deary IJ (2018) Cognitive function in early and later life is associated with blood glucose in older individuals: analysis of the Lothian Birth Cohort of 1936. Diabetologia.  https://doi.org/10.1007/s00125-018-4645-8
  8. 8.
    Kohnert KD, Heinke P, Vogt L, Salzsieder E (2015) Utility of different glycemic control metrics for optimizing management of diabetes. World J Diabetes 6:17–29CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Leong A, Daya N, Porneala B et al (2018) Prediction of type 2 diabetes by hemoglobin a1c in two community-based cohorts. Diabetes Care 41:60–68CrossRefPubMedGoogle Scholar
  10. 10.
    Schnaider Beeri M, Goldbourt U, Silverman JM et al (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63:1902–1907CrossRefPubMedGoogle Scholar
  11. 11.
    Rawlings AM, Sharrett AR, Schneider AL et al (2014) Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 161:785–793CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ekblad LL, Rinne JO, Puukka P et al (2017) Insulin resistance predicts cognitive decline: an 11-year follow-up of a nationally representative adult population sample. Diabetes Care 40:751–758CrossRefPubMedGoogle Scholar
  13. 13.
    Lutski M, Weinstein G, Goldbourt U, Tanne D (2017) Insulin resistance and future cognitive performance and cognitive decline in elderly patients with cardiovascular disease. J Alzheimers Dis 57:633–643CrossRefPubMedGoogle Scholar
  14. 14.
    Crane PK, Walker R, Hubbard RA et al (2013) Glucose levels and risk of dementia. N Engl J Med 369:540–548CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ravona-Springer R, Moshier E, Schmeidler J et al (2012) Changes in glycemic control are associated with changes in cognition in non-diabetic elderly. J Alzheimers Dis 30:299–309CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ravona-Springer R, Heymann A, Schmeidler J et al (2014) Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes. PLoS One 9:e97384CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rawlings AM, Sharrett AR, Mosley TH, Ballew SH, Deal JA, Selvin E (2017) Glucose peaks and the risk of dementia and 20-year cognitive decline. Diabetes Care 40:879–886CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E (2006) Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 10:293–295PubMedGoogle Scholar
  19. 19.
    Scottish Diabetes Survey Monitoring Group (2017) Scottish Diabetes Survey 2016. Available from www.diabetesinscotland.org.uk/Publications/Scottish%20Diabetes%20Survey%202016.pdf. Accessed 16 May 2018
  20. 20.
    Centers for Disease Control and Prevention (2017) National diabetes statistics report, 2017. Available from www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed 16 May 2018
  21. 21.
    Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661–666CrossRefPubMedGoogle Scholar
  22. 22.
    Bangen KJ, Gu Y, Gross AL et al (2015) Relationship between type 2 diabetes mellitus and cognitive change in a multiethnic elderly cohort. J Am Geriatr Soc 63:1075–1083CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Maggi S, Limongi F, Noale M et al (2009) Diabetes as a risk factor for cognitive decline in older patients. Dement Geriatr Cogn Disord 27:24–33CrossRefPubMedGoogle Scholar
  24. 24.
    Rajan KB, Arvanitakis Z, Lynch EB et al (2016) Cognitive decline following incident and preexisting diabetes mellitus in a population sample. Neurology 87:1681–1687CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Gregg EW, Yaffe K, Cauley JA et al (2000) Is diabetes associated with cognitive impairment and cognitive decline among older women? Arch Intern Med 160:174–180CrossRefPubMedGoogle Scholar
  26. 26.
    Mayeda ER, Haan MN, Yaffe K, Kanaya AM, Neuhaus J (2015) Does type 2 diabetes increase rate of cognitive decline in older Mexican Americans? Alzheimer Dis Assoc Disord 29:206–212CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yaffe K, Falvey C, Hamilton N et al (2012) Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 69:1170–1175CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Moran C, Phan TG, Chen J et al (2013) Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 36:4036–4042CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mottus R, Luciano M, Sarr JM, McCarthy MI, Deary IJ (2015) Childhood cognitive ability moderates later-life manifestation of type 2 diabetes genetic risk. Health Psychol 34:915–919CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mottus R, Luciano M, Starr JM, Deary IJ (2013) Diabetes and life-long cognitive ability. J Psychosom Res 75:275–278CrossRefPubMedGoogle Scholar
  31. 31.
    Twig G, Gluzman I, Tirosh A et al (2014) Cognitive function and the risk for diabetes among young men. Diabetes Care 37:2982–2988CrossRefPubMedGoogle Scholar
  32. 32.
    Cukierman-Yaffe T, Kasher-Meron M, Fruchter E et al (2015) Cognitive performance at late adolescence and the risk for impaired fasting glucose among young adults. J Clin Endocrinol Metab 100:4409–4416CrossRefPubMedGoogle Scholar
  33. 33.
    Deary IJ, Weiss A, Batty GD (2010) Intelligence and personality as predictors of illness and death: how researchers in differential psychology and chronic disease epidemiology are collaborating to understand and address health inequalities. Psychol Sci Public Interest 11:53–79CrossRefPubMedGoogle Scholar
  34. 34.
    Hasstedt SJ, Hanis CL, Das SK, Elbein SC (2011) Pleiotropy of type 2 diabetes with obesity. J Hum Genet 56:491–495CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    American Diabetes Association (2018) Older adults: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S119–S125CrossRefGoogle Scholar
  36. 36.
    Punthakee Z, Miller ME, Launer LJ et al (2012) Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 35:787–793CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    American Diabetes Association (2018) Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S55–S64CrossRefGoogle Scholar
  38. 38.
    Fonseca VA (2009) Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32(Suppl 2):S151–S156CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The Joseph Sagol Neuroscience Center, Sheba Medical CenterRamat GanIsrael
  2. 2.Department of NeurologySheba Medical CenterRamat GanIsrael
  3. 3.Sackler School of MedicineTel-Aviv UniversityTel-AvivIsrael
  4. 4.Department of PsychiatryIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations